KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $562.8 million.

  • Castle Biosciences' Liabilities and Shareholders Equity rose 937.12% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 1184.82%. This contributed to the annual value of $531.2 million for FY2024, which is 1718.25% up from last year.
  • As of Q3 2025, Castle Biosciences' Liabilities and Shareholders Equity stood at $562.8 million, which was up 937.12% from $544.7 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Liabilities and Shareholders Equity high stood at $562.8 million for Q3 2025, and its period low was $425.4 million during Q2 2023.
  • Its 5-year average for Liabilities and Shareholders Equity is $469.5 million, with a median of $457.8 million in 2022.
  • As far as peak fluctuations go, Castle Biosciences' Liabilities and Shareholders Equity soared by 26366.45% in 2021, and later crashed by 719.49% in 2023.
  • Castle Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $462.6 million in 2021, then dropped by 3.3% to $447.3 million in 2022, then rose by 1.34% to $453.3 million in 2023, then grew by 17.18% to $531.2 million in 2024, then increased by 5.94% to $562.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $562.8 million in Q3 2025, compared to $544.7 million in Q2 2025 and $501.7 million in Q1 2025.